| [1] |
International Agency for Research on Cancer.Latest global cancer data：Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]．[2020-12-16].
URL
|
| [2] |
Xu B, Hu X, Zheng H, et al. Outcomes of re-treatment with first-line trastuzumab plus a taxane inHER-2 positive metastatic breast cancer patients after (neo) adjuvant trastuzumab: A prospective multicenter study[J]．Oncotarget, 2016，7(31)：5 0643-5 0655.
|
| [3] |
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182.
|
| [4] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial[J]. Lancet, 2019, 393(10 191)：2591-2598.
|
| [5] |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER-2-positive breast cancer (HERA): an open-label, randomised controlled trial[J]. Lancet, 2013, 382(9897): 1021-1028.
|
| [6] |
Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer[J]. Arch Pharm (Weinheim), 2008, 341(8): 465-477.
|
| [7] |
U．S. Food and Drug Administration. FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer[EB/OL]．[2020-12-16].
URL
|
| [8] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744.
|
| [9] |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(1 0075): 1195-1205.
|
| [10] |
Goss PE, Smith IE, O’Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER-2-positive breast cancer: a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(1): 88-96.
|
| [11] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12)：1688-1700.
|
| [12] |
Chan A, Moy B, Mansi J，et al. Final efficacy results of neratinib in HER-2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial[J]. Clin Breast Cancer, 2021, 21(1)：80-91.
|
| [13] |
Chan A, Delaloge S, Holmes FA, et al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016，17(3)：367-377.
|
| [14] |
Iwata H, Masuda N, Kim SB, et al. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER-2-positive breast cancer[J]. Future Oncol, 2019, 15(21)：2489-2501.
|
| [15] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer(V2. 2020) [EB/OL]．[2020-12-16].
URL
|
| [16] |
Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHERLOB study[J]. J Clin Oncol, 2012, 30(16): 1989-1995.
|
| [17] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER-2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2012, 379(9816): 633-640.
|
| [18] |
De Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER-2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response[J]. Lancet Oncol, 2014, 15(10): 1137-1146.
|
| [19] |
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(2): 135-144.
|
| [20] |
Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer[J]．N Engl J Med, 2016, 375(1)：11-22.
|
| [21] |
Jacobs SA, Robidoux A, Abraham J, et al. NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer[J]. Breast Cancer Res, 2019，21(1)：133.
|
| [22] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J]. N Engl J Med, 2001, 344(11): 783-792.
|
| [23] |
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792.
|
| [24] |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study[J]. J Clin Oncol, 2011, 29(3): 264-271.
|
| [25] |
Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA. 31[J]. J Clin Oncol, 2015, 33(14): 1574-1583.
|
| [26] |
Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER-2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2013, 14(6): 461-471.
|
| [27] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol, 2010, 28(7): 1124-1130.
|
| [28] |
Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib[J]. BMC cancer, 2011, 11(1): 1-10.
|
| [29] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer[J]. N Engl J Med, 2006, 355(26): 2733-2743.
|
| [30] |
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER-2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(6): 732-742.
|
| [31] |
Xu B, Kim SB, Inoue K, et al. Neratinib-based therapy in patients with metastatic HER-2-positive breast cancer from Asia[J]. Future Oncol, 2019，15(28)：3243-3253.
|
| [32] |
Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial[J]. JAMA Oncol, 2016, 2(12)：1557-1564.
|
| [33] |
Abraham J, Montero AJ, Jankowitz RC, et al. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER-2-positive breast cancer: NSABP Foundation Trial FB-10[J]．J Clin Oncol, 2019, 37(29)：2601-2609.
|
| [34] |
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER-2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study[J]. Lancet Oncol, 2013, 14(1): 64-71.
|
| [35] |
Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): a phase Ⅲ，randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2015, 33(14): 1564-1573.
|
| [36] |
Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER-2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase Ⅲ study CLEOPATRA[J]. Ann Oncol, 2014, 25(6): 1116-1121.
|
| [37] |
Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER-2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA[J]. Ann Oncol, 2015, 26(1): 113-119.
|
| [38] |
Freedman RA, Gelman RS, Wefel JS, et al. Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases[J]. Clin Oncol, 2016, 34(9)：945-52.
|
| [39] |
Freedman RA, Gelman RS, Agar NYR, et al. Pre- and postoperative neratinib for HER-2-positive breast cancer brain metastases: translational breast cancer research consortium 022[J]. Clin Breast Cancer, 2020，20(2)：145-151.
|
| [40] |
Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases[J]．J Clin Oncol, 2019, 37(13)：1081-1089.
|
| [41] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Central nervous system cancers(V1. 2018) [EB/OL]. [2021-01-15]
URL
|
| [42] |
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER-2-positive metastatic breast cancer previously treated with ≥ 2 HER-2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020，38(27)：3138-3149.
|
| [43] |
Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER-2+ breast cancer brain metastasis[J]．Future Oncol, 2020, 16(7)：247-254.
|
| [44] |
Cocco E, Javier Carmona F, Razavi P, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER-2)[J]. Sci Signal, 2018, 11(551)：eaat9773.
|
| [45] |
Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER-2- and HER-3-mutant cancers[J]. Nature, 2018，554(7691)：189-194.
|
| [46] |
Medford AJ, Dubash TD, Juric D, et al. Blood-based monitoring identifies acquired and targetable driver HER-2 mutations in endocrine-resistant metastatic breast cancer[J]. NPJ Precis Oncol, 2019，3：18.
|
| [47] |
Ma CX, Bose R, Gao F, et al. Neratinib efficacy and circulating tumor DNA detection of HER-2 mutations in HER-2 nonamplified metastatic breast cancer[J]. Clin Cancer Res, 2017，23(19)：5687-5695.
|
| [48] |
Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures[J]. Expert Opin Ther Targets, 2003, 7(2): 215-234.
|
| [49] |
Konecny GE, Pegram MD, Venkatesan N，et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J]. Cancer Res, 2006, 66(3): 1630-1639.
|
| [50] |
Ma F, Li Q, Chen S，et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112.
|
| [51] |
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2009, 27(34): 5838-5847.
|
| [52] |
Arnould L, Gelly M, Penault-Llorca F，et al. Trastuzumab-based treatment of HER-2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism？[J]. Br J Cancer, 2006, 94: 259-267.
|
| [53] |
Franklin MC, Carey KD, Vajdos FF，et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex[J]. Cancer Cell, 2004, 5(4): 317-328.
|
| [54] |
Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER-2, a truncated form of the HER-2 receptor, and response to anti-HER-2 therapies in breast cancer[J]. J Natl Cancer Inst, 2007, 99(8): 628-638.
|
| [55] |
Gallardo A, Lerma E, Escuin D，et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER-2 breast carcinomas[J]. Br J Cancer, 2012, 106: 1367-1373.
|
| [56] |
Mittendorf EA, Wu Y, Scaltriti M，et al. Loss of HER-2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes[J]. Clin Cancer Res, 2009, 15(23): 7381-7388.
|
| [57] |
Nagata Y, Lan KH, Zhou X，et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients[J]. Cancer Cell, 2004, 6(2): 117-127.
|
| [58] |
Canonici A, Gijsen M, Mullooly M, et al. Neratinib overcomes trastuzumab resistance in HER-2 amplified breast cancer[J]. Oncotarget, 2013, 4(10): 1592.
|
| [59] |
Mohd Nafi SN, Generali D, Kramer-Marek G, et al. Nuclear HER-4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER-2 positive breast cancer[J]. Oncotarget, 2014, 5(15): 5934.
|
| [60] |
Mortimer J, Di Palma J, Schmid K, et al. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase Ⅲ ExteNET trial[J]. Breast Cancer Res, 2019, 21(1)：32.
|
| [61] |
Secombe KR, Ball IA, Shirren J, et al. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant[J]. Breast Cancer, 2021，28(1)：99-109.
|
| [62] |
Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER-2-positive early-stage breast cancer: the CONTROL trial[J]. Ann Oncol, 2020, 31(9): 1223-1230.
|
| [63] |
Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER-2+ advanced breast cancer[J]. Eur J Cancer, 2013, 49(18): 3763-3772.
|
| [64] |
Jerusalem G, Lancellotti P, Kim SB. HER-2+ breast cancer treatment and cardiotoxicity: monitoring and management[J]. Breast Cancer Res Treat, 2019, 177(2): 237-250.
|